Knight Therapeutics price target raised to C$7.45 from C$6.25 at Stifel

Stifel analyst Justin Keywood raised the firm’s price target on Knight Therapeutics (KHTRF) to C$7.45 from C$6.25 and keeps a Buy rating on the shares.